Easy to operate for SARS-CoV-2 IgG IgM Antibody Rapid Test Kit

For professional and in vitro diagnostic use only.

[INTENDED USE]
The COVID-19 IgG/IgM Rapid Test device is a lateral flow chromatographic immunoassay for the qualitative detection of antibodies (IgG and IgM) to Novel coronavirus in human Whole Blood/Serum/Plasma. It provides an aid in the diagnosis of infection with Novel coronavirus.

[PERFORMANCE CHARACTERISTICS]

Accuracy

If a person suffered the novel coronaviruses, there are several stages before recovery, like window period, early stage, initial stage, mid-term, and later period. The window period continues 14 days, 3-7days mostly, and no antibody produced at this time. Early stage is about 1-7 days after onset, and the IgM antibody appears, but the concentration is too low to be detected. Initial stage is about 8-14 days after onset, the IgM antibody increases and the IgG antibody appears. Mid-term is about 15-39 days after onset, the IgM antibody decreases gradually and the IgG antibody peaks. The later period is about 1-2 months after onset, and IgM antibody could be detected hardly. Also, everyone is different because of the difference of people’s immune response. For example, the antibody concentration of older people is higher than younger significantly, and the antibody levels in Asymptomatic infected human body are low generally.

A side-by-side comparison was conducted using the Novel coronavirus IgG/IgM Rapid Test and RT-PCR. 200 clinical specimens from Professional Point of Care site were evaluated, 57 were positive and 143 negative. In order to consider the difference of antibody production in people after infection as much as possible, we conducted 10 trails respectively. Base on the results from the clinical studies, the statistical analysis was made as follows:

COVID-19 IgM: the average sensitivity is 81.83% (95% CI: 70.18%~92.58%), the average specificity is 93.93% (95% CI: 88.23%~99.62%) and the total accuracy is 90.67% (95% CI: 87.07%~94.26%).

COVID-19 IgG: the average sensitivity is 92.50% (95% CI: 87.65%~97.35%), the average specificity is 95.53% (95% CI: 92.01%~99.06%) and the total accuracy is 94.67% (95% CI: 91.57%~97.77%).

[SUMMARY]
The novel coronaviruses belong to the β genus. COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.

Hangzhou Aichek Medical Technology Co.,Ltd

Hangzhou Aichek Medical Technology Co.,Ltd is a high-tech company specialises in manufacturing rapid diagnostic and healthcare products.

With five product lines of fertility, infectious diseases, cardiac marker, tumor marker and drug of abuse, our research and development team continues to grow.

Based in Hangzhou, the company has long-term cooperation with various R&D institutions in greater China, the United States and Europe, offering the strongest technical support for the development of the company.

We are also a certified ISO and CE organization. By employing strict quality control system, our management team assures exceptional customer service and high quality products.